for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkermes Plc

ALKS.OQ

Latest Trade

20.87USD

Change

-0.38(-1.79%)

Volume

300,348

Today's Range

20.68

 - 

21.40

52 Week Range

17.11

 - 

37.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.25
Open
21.23
Volume
300,348
3M AVG Volume
34.36
Today's High
21.40
Today's Low
20.68
52 Week High
37.63
52 Week Low
17.11
Shares Out (MIL)
157.52
Market Cap (MIL)
3,347.35
Forward P/E
40.95
Dividend (Yield %)
--

Next Event

Q4 2019 Alkermes Plc Earnings Release

Latest Developments

More

FDA Sends Warning Letter To Alkermes Over A Print Ad For Vivitrol For Intramuscular Use

Alkermes Submits New Drug Application To U.S. FDA For ALKS 3831

Alkermes Submits New Drug Application To U.S. FDA For Alks 3831 For Treatment Of Schizophrenia And Bipolar I Disorder

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alkermes Plc

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

Connaught HSE, 1 Burlington Road

+353.1.7728000

http://www.alkermes.com

Executive Leadership

Richard F. Pops

Chairman of the Board, Chief Executive Officer

James M. Frates

Chief Financial Officer, Senior Vice President, Treasurer

Iain M. Brown

Senior Vice President - Finance, Chief Accounting Officer

David Joseph Gaffin

Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

Michael J. Landine

Senior Vice President - Corporate Development, Chief Risk Officer

Key Stats

2.67 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.7K

2017

0.9K

2018

1.1K

2019(E)

1.2K
EPS (USD)

2016

-0.070

2017

0.170

2018

0.610

2019(E)

0.519
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.12
Price To Book (MRQ)
3.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
26.00
LT Debt To Equity (MRQ)
25.73
Return on Investment (TTM)
-14.14
Return on Equity (TTM)
-11.42

Latest News

Latest News

BRIEF-Alkermes Q1 GAAP Loss Per Share $0.40

* Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION

BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461

* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

BRIEF-Alkermes Says CEO's FY 2017 Total Compensation Was $9.4 Mln VS $9.6 Mln In FY 2016

* ALKERMES PLC SAYS CHAIRMAN AND CEO RICHARD POPS' FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $9.6 MLN IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GPYT4o) Further company coverage:

BRIEF-Alkermes CEO Says Does Not Believe Additional Trials Of Depression Drug Necessary

* CEO SAYS "WE DON'T BELIEVE ANY ADDITIONAL CLINICAL TRIALS ARE NECESSARY" ON CONF CALL WHEN ASKED ABOUT FDA'S DECISION ON ITS DEPRESSION DRUG Further company coverage:

FDA refuses to review Alkermes' depression treatment, seeks more trials

Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval, citing a lack of evidence of its effectiveness.

FDA rejects application to review Alkermes' depression treatment

Alkermes Plc said on Monday the U.S. Food and Drug Administration rejected the application seeking approval for its experimental depression drug, citing insufficient evidence of effectiveness.

BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461

* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461

BRIEF-Alkermes Says Co, Units Entered Amendment To Amended And Restated Credit Agreement

* ALKERMES PLC SAYS ON MARCH 26, CO ,UNITS ENTERED AMENDMENT TO AMENDED & RESTATED CREDIT AGREEMENT, DATED AS OF SEPTEMBER 16, 2011 - SEC FILING

BRIEF-Alkermes Appoints James Robinson As President And Chief Operating Officer

* ALKERMES APPOINTS JAMES ROBINSON AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Alkermes PLC Reports Q4 Non-Gaap Earnings Per Share $0.31

* REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DEC. 31, 2017 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2018

BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER

* ALKERMES SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:

BRIEF-Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes

* PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2A7WmiG) Further company coverage:

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

BRIEF-Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr

* ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION - SEC FILING

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up